September 2025
Company Highlights Business Review Financial Review Appendix
Contents
1H25 Financial Results
20.8%
22.6%
18.1%
9.6%
5.3%
2.0%
5.5%
16.1%
7.7%
$Cardiovascular Orthopedics CRM
Endovascular Neurovascular Heart valve Surgical robots Others
$50.6%
2.7%
1.3%
8.7%
29.0%
The PRC North America Europe
Asia (excluding the PRC) South America
Others
Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.
Cardiovascular
EBITDA
$128M
⯅116%YOY
Going-abroad
Revenue
~$60M
⯅57.3%YOY
Net profit ▲64.4%YOY
Increasing sales contribution of active device
Orthopedics
CRM
Endovascular
Neurovascular
Net loss narrowed 58%YOY
EBITDA ▲28.5%YOY
EBITDA breakeven
Net profit $43mn
Adjusted net profit ratio 39%
Surgical Robot
Structural Heart
Net loss at $0.4mn, narrowed 96.2%YOY Net loss narrowed 58.9%YOY
FDA approval for domestic total
knee system
Not Applicable Overseas rev. ▲95% Overseas rev. ▲67%
Overseas rev. ▲235%
Overseas rev. ▲189%
Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.
1H25 Portfolio Highlights
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |